Core Viewpoint - BYD Company Limited announced that as of February 28, 2026, its total statutory/registered capital amounts to 9.117 billion yuan, with no changes from the previous month [1] Group 1: Capital Structure - The total number of H shares is 3.683 billion, while A shares amount to 5.434 billion, both remaining unchanged from the previous month [1] - The issued shares consist of 3.683 billion H shares and 5.434 billion A shares, with no treasury shares reported, also unchanged from the previous month [1] Group 2: Compliance - The company confirmed that it meets the applicable public float requirements [1]

Summary of Key Points Core Viewpoint - China CNR Corporation announced that as of February 28, 2026, the company's registered capital remains at 28.699 billion yuan, showing no change from the previous month [1] Group 1: Capital Structure - The total registered capital of the company is 28.699 billion yuan, unchanged from the previous month [1] - The number of H-shares is 4.371 billion shares, while the number of A-shares is 24.328 billion shares, both remaining stable compared to the previous month [1] - The nominal value of both H-shares and A-shares is 1 yuan [1] Group 2: Issued Shares - The number of issued H-shares is 4.371 billion shares, and the number of issued A-shares is 24.328 billion shares, with no changes from the previous month [1] - H-shares have met the applicable public holding requirements [1]

Core Viewpoint - BeiGene has demonstrated strong execution in Q4 2025, achieving significant product revenue growth and solid cash flow, with its lead product, Brukinsa (Zebutinib), becoming the top BTK inhibitor globally [1][4][17]. Financial Performance - Q4 2025 product revenue reached $1.5 billion, a 33% year-over-year increase, with Brukinsa global revenue of $1.1 billion, up 38% [3][17]. - For the full year 2025, Brukinsa generated $3.9 billion in global revenue, reflecting a 49% increase [3][17]. - Gross margin improved to 87%, with operating profit of $447 million and GAAP net profit of $287 million for Q4 2025 [3][19]. - The company expects total revenue for 2026 to be between $6.2 billion and $6.4 billion, with GAAP operating expenses projected at $4.7 billion to $4.9 billion [3][21]. Product Development and Pipeline - In 2025, BeiGene made significant progress in R&D, with the approval of ZS in China for relapsed/refractory MCL and CLL, and ongoing regulatory reviews in the US and EU [2][8]. - The company is advancing multiple clinical trials, including three Phase 3 trials for BTK degraders and a combination therapy for HER2-positive gastric cancer [2][8][14]. - BeiGene aims to establish Brukinsa as a foundational treatment in CLL, with plans to expand its use in fixed-duration treatment regimens [10][11]. Market Position and Strategy - Brukinsa has established itself as the leading BTK inhibitor, with a market share of approximately 50% in the CLL treatment space [7][27]. - The company is targeting three ambitious goals for CLL innovation, focusing on improving patient outcomes and treatment options [6][10]. - BeiGene is also expanding its pipeline beyond CLL, with ongoing research in various hematologic malignancies and solid tumors [11][12][13]. Future Catalysts - Key upcoming milestones include the initiation of a global Phase 3 study comparing ZS with another oral fixed-duration treatment in newly diagnosed CLL patients [16][21]. - The company plans to submit a marketing application for ZS in combination with chemotherapy for HER2-positive gastric cancer in mid-2026 [16][21]. - BeiGene is also set to report on several concept validation studies in immunology throughout 2026 [16].

Group 1 - European luxury stocks opened lower, with LVMH down 4.3% [1] - Richemont shares fell by 4.7% [1] - Swatch Group's stock decreased by 6% [1]

Group 1 - The core point of the article is that Airbus's stock price has decreased by 3.3% due to the escalating conflict in the Middle East [1] Group 2 - The news source is from Financial界 AI Telegram [2]

Core Viewpoint - BYD's sales performance in February demonstrates significant growth, with overseas sales surpassing domestic sales for the first time, highlighting the success of its globalization strategy [1] Sales Performance - In February, BYD achieved a total sales volume of 190,190 vehicles, with overseas sales reaching 100,151 units, marking a year-on-year increase of 41.4% [1] - The breakdown of sales includes 187,782 passenger vehicles, with the Dynasty and Ocean series contributing 165,013 units, while the Fangchengbao, Tengshi, and Yangwang models delivered 17,036, 5,501, and 232 units respectively [1] Cumulative Sales Data - For the period of January to February 2026, BYD's cumulative sales reached 400,241 vehicles, with overseas sales exceeding 200,000 units and cumulative new energy vehicle sales surpassing 15.5 million units [1] Globalization Strategy - The surpassing of domestic sales by overseas sales is a key achievement of BYD's globalization strategy, particularly in core markets such as Southeast Asia, Latin America, and Europe [1] - BYD's diverse product matrix and localized operations have significantly enhanced its brand influence in these regions [1] Industry Impact - This achievement not only reflects BYD's technological advantages in the new energy sector but also serves as a new model for Chinese automotive brands expanding internationally [1] - It signifies a shift in the Chinese automotive industry from merely exporting products to enhancing brand recognition globally [1]

Core Viewpoint - The global market is under pressure due to geopolitical events, but A-shares remain stable, with strong performance from sectors like oil, military, non-ferrous metals, and coal. BYD, a leading automotive company, saw its stock price rise over 4%, indicating active trading dynamics [1]. Group 1: BYD Performance - BYD's stock price increased significantly, reaching a peak of 93.69 yuan, with a notable trading volume, reflecting a robust market interest [1]. - The market speculation around BYD is primarily focused on its global expansion prospects and technological innovations, with expectations that its global delivery volume will reach 6 million units by 2026, contributing 1.5 million units from overseas markets [2]. - BYD's recent sales data shows that in February, it sold 190,200 vehicles, with overseas sales surpassing domestic sales for the first time, totaling 100,200 units [3]. Group 2: Technological Advancements - BYD has made significant progress in solid-state battery technology, achieving a key milestone by passing automotive-grade testing, marking a transition from laboratory concepts to industrial application [3]. - The company is also focusing on advancements in smart driving technologies, which are attracting attention from the capital market [2]. Group 3: Industry Comparisons - Chery, another automotive player, reported strong sales figures, with a total of 160,800 vehicles sold in February, including 124,900 units exported, representing a year-on-year growth of 41.5% [3]. - In the first two months of the year, Chery's cumulative sales reached 361,000 vehicles, with exports accounting for 244,500 units [3].

Group 1 - The top 20 stocks with significant capital inflow include Zhongji Xuchuang (1.706 billion), BYD (1.590 billion), and Xinyi Sheng (1.447 billion) [1] - Zhongji Xuchuang experienced a price increase of 6.74%, while BYD rose by 4.4% [2] - The defense sector shows strong performance with Lei Ke Defense and China Satellite increasing by 10.02% and 6.52% respectively [2] Group 2 - Other notable stocks include Feilong Co. (10% increase), Dongshan Precision (4.01% increase), and Hengtong Optic-Electric (6.36% increase) [2][3] - The energy sector is represented by TBEA (3.1% increase) and Changjiang Electric Power (2.04% increase) [2] - Agricultural Bank saw a modest increase of 1.88% with a capital inflow of 3.17 billion [3]

Core Viewpoint Geely Auto Group has demonstrated significant growth in both domestic and international markets, particularly in the new energy vehicle (NEV) segment, with a focus on high-end product offerings and user value enhancement. Group 1: Sales Performance - Geely Auto Group ranked first in vehicle sales with 206,160 units delivered, followed by BYD with 187,782 units and Chery Group with 160,765 units [1] - In February, NEV sales reached 117,488 units, marking a 19% year-on-year increase, while cumulative NEV sales for January-February reached 241,740 units, up 10% [2] - Geely's global luxury tech brand Zeekr sold 23,867 units in February, achieving a 70% year-on-year growth [5] Group 2: Product Development and Launches - Geely is expanding its high-end product matrix, with the Zeekr 8X SUV set to launch in Q2, featuring advanced driving assistance systems [5] - The Geely Galaxy brand has seen strong sales, with the Galaxy E5 surpassing 250,000 units and the Galaxy M7 making its global debut in Milan [7] - The Geely China Star brand sold 81,809 units in February, with the high-end series contributing 25,458 units [9] Group 3: International Expansion - Geely's overseas sales reached 60,879 units in February, a substantial increase of 138% year-on-year, with NEV exports accounting for 40,852 units, or 67% of total overseas sales [10] - The launch of the Galaxy Starship 7 EM-i in Greece and the introduction of multiple models in Uzbekistan signify Geely's commitment to expanding its international footprint [12] - Geely has established a robust after-sales network in Uzbekistan, aiming for 100% coverage in core cities over the next three years [12] Group 4: Sustainability and Recognition - Geely Auto was included in S&P Global's "Global Sustainability Yearbook 2026," recognized as the only Chinese automaker among eight global manufacturers for its outstanding ESG performance [14] - The company aims to continue its sustainable development path, focusing on technological innovation and product upgrades to enhance user value [14]

Core Viewpoint - Fosun International (00656.HK) announced a share buyback plan with a total amount not exceeding HKD 1 billion, citing that the current stock price does not reflect the company's long-term value and expressing confidence in its future development [1] Group 1: Buyback Announcement - The company plans to conduct share buybacks from the release of its 2025 annual results until the 2026 annual general meeting [1] - The buyback is intended to be conducted in an orderly manner within the legal and regulatory framework [1] - The announcement reflects the company's confidence in its long-term growth prospects and prudent consideration of shareholder interests [1] Group 2: Business Performance - In 2026, Fosun's core sectors, including biomedicine, cultural tourism, and insurance, have shown strong momentum [2] - The biopharmaceutical sector has made significant strides, with agreements in Japan potentially exceeding USD 300 million and a global exclusive licensing agreement with Pfizer worth over USD 2 billion [2] - The cultural tourism sector has seen impressive performance, with Shanghai Yuyuan receiving nearly 1.2 million visitors during the Spring Festival, a year-on-year increase of over 20% [2] Group 3: Insurance Sector Growth - Fosun's insurance companies reported substantial growth in 2025, with Fosun United Health Insurance achieving revenue of CNY 7.84 billion, a 50% increase year-on-year [3] - Fosun's life insurance segment recorded revenue of CNY 12.598 billion, a 36.17% increase, and a net profit of CNY 647 million, up over 450% year-on-year [3] - The robust growth in core businesses is seen as a catalyst for the buyback initiative [3] Group 4: Previous Buyback Activity - Prior to the announcement, Fosun International repurchased 13.027 million shares for HKD 48.2354 million on February 27 [3] - Since January 1, 2022, the company has repurchased a total of 258.859 million shares, representing approximately 3.17% of the total issued shares, with a total expenditure of about HKD 1.19 billion [3] Group 5: Valuation Perspective - The announcement emphasizes that the buyback aligns with the overall interests of the company and its shareholders at the current valuation level [4]